BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy

Key Inclusion Criteria: * Body weight ≤133 kg. * Leg pain radiating, diagnosed as being due to painful lumbar radiculopathy or lumbosacral radiculopathy, the diagnosis of which occurred within ≥6 months and ≤5 years of the time of randomization. * Objective, documented evidence of painful lumbar radiculopathy involvement * Lower back pain * Leg pain * Male and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 3 months after their last dose of study treatment. Key Exclusion Criteria: * History of or positive test result at screening for human immunodeficiency virus, or for hepatitis C virus antibody, or current Hepatitis B infection. * Clinically significant diseases or conditions as determined by the investigator. * Major surgery within 30 days prior to the Screening Visit or that is scheduled to occur during the study. * Previous participation in a study with neurotrophic factors (e.g., nerve growth factor). * Participation in a study with another investigational drug or approved therapy for investigational use within 3 months prior to Day 1. * Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec Inc. (Biogen Idec), make the subject unsuitable for enrollment NOTE: Other protocol-defined inclusion/exclusion criteria may apply